Sugi Predict

Sugi Predict / Compounds / SCHEMBL29469826

SCHEMBL29469826

SCHEMBL29469826

CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)C(C)C

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.54
▸ GLP1R P43220 7/20 0.51
▸ PTH1R Q03431 3/20 0.51
▸ SCTR P47872 1/20 0.51
▸ GCGR P47871 4/20 0.51
▸ TFPI P10646 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ CALCR P30988 1/20 0.49
▸ C5AR1 P21730 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30862334 0.92 KEAP1 (0.58) KEAP1GLP1RPTH1RSCTRRXFP1
SCHEMBL30930541 0.90 GLP1R (0.54) GLP1RSCTRGCGRTFPI
SCHEMBL31211842 0.90 KEAP1 (0.57) KEAP1GLP1RPTH1RSCTRGCGR
SCHEMBL31211763 0.90 KEAP1 (0.57) KEAP1GLP1RPTH1RSCTRGCGR
SCHEMBL30432625 0.88 PTH1R (0.59) KEAP1GLP1RPTH1RSCTRRXFP1
SCHEMBL30432179 0.88 CALCR (0.57) KEAP1GLP1RPTH1RSCTRGCGR
SCHEMBL11123257 0.88 C5AR1 (0.47) KEAP1GLP1RGCGRRXFP1C5AR1
SCHEMBL11123246 0.88 C5AR1 (0.47) KEAP1GLP1RGCGRRXFP1C5AR1
SCHEMBL30903281 0.87 KEAP1 (0.54) KEAP1GLP1RPTH1RRXFP1CALCR
SCHEMBL31182576 0.87 PTH1R (0.58) GLP1RPTH1RSCTRGCGRTFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4229045-B1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BROAD INST INC (US) 2025-11-12 — — EP disclosed
US-12357603-B2 Acyl sulfonamides for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2025-07-15 — — US disclosed
CN-118666972-A Antibacterial peptide and application thereof in preventing and treating citrus yellow dragon disease 中国科学院微生物研究所 2024-09-20 — — CN disclosed
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-29 — — US disclosed
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 — — US disclosed
US-20240279313-A1 BARRIER FUNCTION PRESERVING PEPTIDES FOR MEMBRANES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-22 — — US disclosed
EP-4384199-A2 BARRIER FUNCTION PRESERVING PEPTIDES FOR MEMBRANES The Regents of University of California (US) 2024-06-19 — — EP disclosed
EP-4229045-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute Inc. (US) 2023-08-23 — — EP disclosed
EP-4229048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute, Inc. (US) 2023-08-23 — — EP disclosed
EP-3959202-B1 ACYL SULFONAMIDES FOR TREATING CANCER BAYER AG (DE) 2023-08-16 — — EP disclosed
WO-2023018876-A2 BARRIER FUNCTION PRESERVING PEPTIDES FOR MEMBRANES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-16 — — WO disclosed
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. 2022-07-21 — — US disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 — — WO disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A KEAP1 1622/4885GLP1R 4245/4885PTH1R 4741/4885
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A KEAP1 1639/4885GLP1R 3649/4885PTH1R 4522/4885
US-12357603-B2 Acyl sulfonamides for treating cancer KAT6A, KAT6B, KAT2A KEAP1 1639/4885GLP1R 3649/4885PTH1R 4522/4885
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A KEAP1 1835/4885GLP1R 4052/4885PTH1R 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback